FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 351:100-102 July 1, 2004 Number 1 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Coombes, R. C. PubMed Citation

To the Editor: Coombes et al. (March 11 issue)¹ report an important advantage in terms of disease-free survival with the use of adjuvant exemestane after initial treatment with tamoxifen. Adjuvant postmastectomy radiotherapy might have influenced the risk of locoregional recurrence. Adjuvant radiotherapy reduces the annual odds of locoregional failure by 75 percent.² However, the policy on the use of postmastectomy radiotherapy in the trial is not stated. More than half the patients (1222 in the exemestane group and 1235 in the tamoxifen-only group) underwent mastectomy. Whereas postmastectomy radiotherapy would be standard practice³ for patients with four or more nodes (321 . . . [Full Text of this Article]

This article has been cited by other articles:

• Mann, B. S., Johnson, J. R., Kelly, R., Sridhara, R., Williams, G., Pazdur, R. (2005). Letrozole in the Extended Adjuvant Treatment of Postmenopausal Women with History of Early-Stage Breast Cancer Who Have Completed 5 Years of Adjuvant Tamoxifen. Clin. Cancer Res. 11: 5671-5677 [Abstract] [Full Text]